Ajax loader
By using our website, you agree to our use of cookies as described in Cookie Policy.

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Search results for: Astrazeneca

FRANCE-POLITICS/
RTS2Z4AB
January 20, 2020
French President Emmanuel Macron reacts during a visit at the AstraZeneca factory in Dunkirk, France...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron reacts during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z4A9
January 20, 2020
French President Emmanuel Macron, next to French Health and Solidarity Minister Agnes Buzyn, speaks with...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron, next to French Health and Solidarity Minister Agnes Buzyn, speaks with an employee during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z49Y
January 20, 2020
French President Emmanuel Macron speaks with an employee during a visit at the AstraZeneca factory in...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks with an employee during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z49I
January 20, 2020
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z49D
January 20, 2020
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z49A
January 20, 2020
French President Emmanuel Macron speaks with an employee during a visit at the AstraZeneca factory in...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks with an employee during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z491
January 20, 2020
French President Emmanuel Macron speaks with an employee during a visit at the AstraZeneca factory in...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks with an employee during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z48Y
January 20, 2020
French President Emmanuel Macron, next to French Health and Solidarity Minister Agnes Buzyn, speaks with...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron, next to French Health and Solidarity Minister Agnes Buzyn, speaks with an employee during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z48U
January 20, 2020
French President Emmanuel Macron speaks with an employee during a visit at the AstraZeneca factory in...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks with an employee during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z489
January 20, 2020
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z482
January 20, 2020
French President Emmanuel Macron, next to French Health and Solidarity Minister Agnes Buzyn, speaks with...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron, next to French Health and Solidarity Minister Agnes Buzyn, speaks with an employee during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z480
January 20, 2020
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z47G
January 20, 2020
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z47E
January 20, 2020
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
FRANCE-POLITICS/
RTS2Z46J
January 20, 2020
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France...
Dunkirk, France
French President Emmanuel Macron visits AstraZeneca factory in Dunkirk
French President Emmanuel Macron speaks during a visit at the AstraZeneca factory in Dunkirk, France January 20, 2020. Denis Charlet/Pool via REUTERS
CHINA-TRADE/EXPO-ASTRAZENECA
RTX77O7Z
November 06, 2019
Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with...
Shanghai, China
Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with...
Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with Reuters in Shanghai, China November 4, 2019. Picture taken November 4, 2019. REUTERS/Brenda Goh
CHINA-TRADE/EXPO-ASTRAZENECA
RTX77O7Y
November 06, 2019
Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with...
Shanghai, China
Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with...
Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with Reuters in Shanghai, China November 4, 2019. Picture taken November 4, 2019. REUTERS/Brenda Goh
USA-STOCKS/
RTS2GU51
April 08, 2019
The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the...
New York, UNITED STATES
The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the...
The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid
RUSSIA-PUTIN/BUSINESS
RTS2DY5H
March 20, 2019
Russian President Vladimir Putin (L, front) greets BP Chief Executive Robert Dudley (R) and Chief Executive...
Moscow, Russia
Russian President Putin attends a meeting with businessmen in Moscow
Russian President Vladimir Putin (L, front) greets BP Chief Executive Robert Dudley (R) and Chief Executive of AstraZeneca Pascal Soriot (2nd R) during a meeting with businessmen at the Kremlin in Moscow, Russia March 20, 2019. Alexander Nemenov/Pool via REUTERS
ASTRAZENECA-CHINA/
RTS21XIQ
September 19, 2018
A projection of a doctor is seen on a screen at the British pharmaceutical company AstraZeneca’s China...
Wuxi, China
Projection of a doctor is seen on a screen at the British pharmaceutical company AstraZeneca’s China...
A projection of a doctor is seen on a screen at the British pharmaceutical company AstraZeneca’s China Commercial Innovation Centre (CCIC) in Wuxi, Jiangsu province, China September 15, 2018. Picture taken September 15, 2018. REUTERS/Adam Jourdan
ASTRAZENECA-CHINA/
RTS21XIP
September 19, 2018
The logo of the British pharmaceutical company AstraZeneca is seen at the company's China Commercial...
Wuxi, China
The logo of the British pharmaceutical company AstraZeneca is seen at the company's China Commercial...
The logo of the British pharmaceutical company AstraZeneca is seen at the company's China Commercial Innovation Centre (CCIC) in Wuxi, Jiangsu province, China, September 15, 2018. Picture taken September 15, 2018. REUTERS/Adam Jourdan
USA-STOCKS/
RTS1F5IH
October 04, 2017
Traders work at the post where AstraZeneca is traded on the floor of the New York Stock Exchange (NYSE)...
New York, UNITED STATES
Traders work at the post where AstraZeneca is traded on the floor of the NYSE in New York
Traders work at the post where AstraZeneca is traded on the floor of the New York Stock Exchange (NYSE) in New York, U.S., October 4, 2017. REUTERS/Brendan McDermid
ASTRAZENECA-CANCER/ C
RTX35XTD
May 15, 2017
Bar charts showing sales forecasts for cancer immunotherapy drugs
Cancer drug forecasts EPS C
Bar charts showing sales forecasts for cancer immunotherapy drugs
ASTRAZENICA-RESULTS/
RTX2S8JA
November 07, 2016
The logo of AstraZeneca is seen on a medication package in a pharmacy in London, Britain, April 28, 2014....
London, United Kingdom
The logo of AstraZeneca is seen on a medication package in a pharmacy in London
The logo of AstraZeneca is seen on a medication package in a pharmacy in London, Britain, April 28, 2014. REUTERS/Stefan Wermuth/File Photo GLOBAL BUSINESS WEEK AHEAD PACKAGE - SEARCH 'BUSINESS WEEK AHEAD NOV 7' FOR ALL IMAGES
BRITAIN-EU/PHARMACEUTICALS-AEROSPACE
RTX2R7XP
October 31, 2016
The logo of AstraZeneca is seen on a medication package in a pharmacy in London, Britain, April 28, 2014....
London, United Kingdom
The logo of AstraZeneca is seen on a medication package in a pharmacy in London
The logo of AstraZeneca is seen on a medication package in a pharmacy in London, Britain, April 28, 2014. REUTERS/Stefan Wermuth/File Photo
ASTRAZENECA-RESULTS/
RTSK0ZF
July 28, 2016
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File...
Macclesfield, United Kingdom
A sign is seen at an AstraZeneca site in Macclesfield
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo
ASTRAZENECA-CEO/ASTRAZENECA-PRESIDENTE C
RTX6YLFK
May 18, 2016
Charts comparing earnings per share and revenue for 2012-2019. Diagrama que compara las ganancias por...
AstraZeneca's trough years ASTRAZENECA PRESIDENTE C
Charts comparing earnings per share and revenue for 2012-2019. Diagrama que compara las ganancias por acción e ingresos del período 2012-2019. 16 cm de ancho. (SGN11)
ASTRAZENECA-CEO/ C
RTSESC2
May 18, 2016
Charts comparing earnings per share and revenue for 2012-2019.
AstraZeneca's trough years EPS C
Charts comparing earnings per share and revenue for 2012-2019.
ASTRAZENECA-CEO/
RTSEM7D
May 17, 2016
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London May 13, 2014. REUTERS/Toby Melville/File Photo
ASTRAZENECA-RESULTS/
RTX2BMXY
April 26, 2016
A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil...
Macclesfield, United Kingdom
A man walks past a sign at an AstraZeneca site in Macclesfield
A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo
ASTRAZENECA-RESULTS/
RTX2BMXT
April 26, 2016
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File...
Macclesfield, United Kingdom
A sign is seen at an AstraZeneca site in Macclesfield
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo
ASTRAZENECA-RESULTS/
RTX2BGVH
April 25, 2016
A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil...
Macclesfield, United Kingdom
A man walks past a sign at an AstraZeneca site in Macclesfield
A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo GLOBAL BUSINESS WEEK AHEAD PACKAGE - SEARCH 'BUSINESS WEEK AHEAD APRIL 25' FOR ALL IMAGES
ASTRAZENECA-PFIZER/
RTR3PT61
May 19, 2014
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. Britain's Prime...
Macclesfield, United Kingdom
A sign is seen at an AstraZeneca site in Macclesfield
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. Britain's Prime Minister David Cameron said the government would continue to talk to both Pfizer and AstraZeneca after the British drugmaker on Monday rejected a sweetened offer from the U.S. company. REUTERS/Phil Noble (BRITAIN - Tags: BUSINESS HEALTH)
ASTRAZENECA-PFIZER/
RTR3PT5Q
May 19, 2014
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. Britain's Prime...
Macclesfield, United Kingdom
A sign is seen at an AstraZeneca site in Macclesfield
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. Britain's Prime Minister David Cameron said the government would continue to talk to both Pfizer and AstraZeneca after the British drugmaker on Monday rejected a sweetened offer from the U.S. company. REUTERS/Phil Noble (BRITAIN - Tags: BUSINESS HEALTH)
ASTRAZENECA-PFIZER/
RTR3PT5D
May 19, 2014
A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. Britain's...
Macclesfield, United Kingdom
A man walks past a sign at an AstraZeneca site in Macclesfield
A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. Britain's Prime Minister David Cameron said the government would continue to talk to both Pfizer and AstraZeneca after the British drugmaker on Monday rejected a sweetened offer from the U.S. company. REUTERS/Phil Noble (BRITAIN - Tags: BUSINESS HEALTH)
ASTRAZENECA-PFIZER
RTR3P3VK
May 14, 2014
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves after appearing at a commons science...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P3SA
May 14, 2014
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing...
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P3RM
May 14, 2014
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing...
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
BRITAIN
RTR3P3NR
May 14, 2014
Pfizer's head of PharmaTherapeutics R&D Rod MacKenzie leaves after appearing at a commons science committee...
London, United Kingdom
Pfizer's head of PharmaTherapeutics R&D Rod MacKenzie leaves after appearing at a commons science committee...
Pfizer's head of PharmaTherapeutics R&D Rod MacKenzie leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P3MJ
May 14, 2014
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing...
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P3KZ
May 14, 2014
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis...
London, United Kingdom
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis...
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS HEALTH EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P3KL
May 14, 2014
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis...
London, United Kingdom
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis...
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS HEALTH EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P3K8
May 14, 2014
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis...
London, United Kingdom
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis...
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS HEALTH EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P3D8
May 14, 2014
Pfizer Chief Executive Ian Read (C) leaves after appearing at a commons science committee hearing at...
London, United Kingdom
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis...
Pfizer Chief Executive Ian Read (C) leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS HEALTH EMPLOYMENT TPX IMAGES OF THE DAY)
ASTRAZENECA-PFIZER
RTR3P3BD
May 14, 2014
Pfizer worldwide research and development president Mikael Dolsten leaves after appearing at a commons...
London, United Kingdom
Pfizer worldwide research and development president Mikael Dolsten leaves after appearing at a commons...
Pfizer worldwide research and development president Mikael Dolsten leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
BRITAIN
RTR3P3AA
May 14, 2014
Pfizer's head of PharmaTherapeutics R&D Rod MacKenzie leaves after appearing at a commons science committee...
London, United Kingdom
Pfizer's head of PharmaTherapeutics R&D Rod MacKenzie leaves after appearing at a commons science committee...
Pfizer's head of PharmaTherapeutics R&D Rod MacKenzie leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P39C
May 14, 2014
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis...
London, United Kingdom
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis...
Pfizer Chief Executive Ian Read leaves after appearing at a commons science committee hearing at Portcullis House in London May 14, 2014. Pfizer said it would ringfence the development of important drugs if it acquired AstraZeneca, rejecting a charge from the British company that a takeover would disrupt important research and put lives at risk. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS HEALTH EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P2A9
May 14, 2014
Pfizer's head of PharmaTherapeutics R&D Rod MacKenzie arrives to appear at a commons science committee...
London, United Kingdom
Pfizer's head of PharmaTherapeutics R&D Rod MacKenzie arrives to appear at a commons science committee...
Pfizer's head of PharmaTherapeutics R&D Rod MacKenzie arrives to appear at a commons science committee hearing at Portcullis House in London May 14, 2014. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P28H
May 14, 2014
Pfizer worldwide research and development president Mikael Dolsten arrives to appear at a commons science...
London, United Kingdom
Pfizer worldwide research and development president Mikael Dolsten arrives to appear at a commons science...
Pfizer worldwide research and development president Mikael Dolsten arrives to appear at a commons science committee hearing at Portcullis House in London May 14, 2014. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P25O
May 14, 2014
Pfizer Chief Executive Ian Read arrives to appear at a commons science committee hearing at Portcullis...
London, United Kingdom
Pfizer Chief Executive Ian Read arrives to appear at a commons science committee hearing at Portcullis...
Pfizer Chief Executive Ian Read arrives to appear at a commons science committee hearing at Portcullis House in London May 14, 2014. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
ASTRAZENECA-PFIZER
RTR3P23Z
May 14, 2014
Pfizer Chief Executive Ian Read arrives to appear at a commons science committee hearing at Portcullis...
London, United Kingdom
Pfizer Chief Executive Ian Read arrives to appear at a commons science committee hearing at Portcullis...
Pfizer Chief Executive Ian Read arrives to appear at a commons science committee hearing at Portcullis House in London May 14, 2014. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS EMPLOYMENT)
ASTRAZENECA-PFIZER/
RTR3OYW7
May 13, 2014
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London May 13, 2014. U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs. REUTERS/Toby Melville (BRITAIN - Tags: POLITICS HEALTH BUSINESS)
ASTRAZENECA-PFIZER/
RTR3OY4L
May 13, 2014
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London May 13, 2014. U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs. REUTERS/Toby Melville (BRITAIN - Tags: POLITICS HEALTH BUSINESS)
ASTRAZENECA-PFIZER/
RTR3OY3W
May 13, 2014
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London May 13, 2014. U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs. REUTERS/Toby Melville (BRITAIN - Tags: POLITICS HEALTH BUSINESS)
ASTRAZENECA-PFIZER/
RTR3OY3U
May 13, 2014
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London May 13, 2014. U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs. REUTERS/Toby Melville (BRITAIN - Tags: POLITICS HEALTH BUSINESS)
ASTRAZENECA-PFIZER/
RTR3OY29
May 13, 2014
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves a television studio at Millbank in London May 13, 2014. U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs. REUTERS/Toby Melville (BRITAIN - Tags: POLITICS HEALTH BUSINESS)
ASTRAZENECA-PFIZER/
RTR3OXXX
May 13, 2014
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves after appearing at a parliamentary business...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a parliamentary business and enterprise...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves after appearing at a parliamentary business and enterprise committee hearing at Portcullis House in London May 13, 2014. U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS HEADSHOT HEALTH EMPLOYMENT)
ASTRAZENECA-PFIZER/
RTR3OXJR
May 13, 2014
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves after appearing at a parliamentary business...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a parliamentary business and enterprise...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves after appearing at a parliamentary business and enterprise committee hearing at Portcullis House in London May 13, 2014. U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs. REUTERS/Neil Hall (BRITAIN - Tags: BUSINESS POLITICS HEALTH EMPLOYMENT)
ASTRAZENECA-PFIZER/
RTR3OXIW
May 13, 2014
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves after appearing at a parliamentary business...
London, United Kingdom
Chief Executive of AstraZeneca Pascal Soriot leaves after appearing at a parliamentary business and enterprise...
Chief Executive of AstraZeneca Pascal Soriot smiles as he leaves after appearing at a parliamentary business and enterprise committee hearing at Portcullis House in London May 13, 2014. U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS HEALTH EMPLOYMENT)
ASTRAZENECA-PFIZER/
RTR3OXIB
May 13, 2014
AstraZeneca's head of innovative medicines Mene Pangalos leaves after appearing at a parliamentary business...
London, United Kingdom
AstraZeneca's head of innovative medicines Mene Pangalos leaves after appearing at a parliamentary business...
AstraZeneca's head of innovative medicines Mene Pangalos leaves after appearing at a parliamentary business and enterprise committee hearing at Portcullis House in London May 13, 2014. U.S. drugmaker Pfizer hinted it could raise its proposed $106 billion offer if AstraZeneca would only engage in talks, as its boss was grilled by British lawmakers on his commitment to British research spending and jobs. REUTERS/Luke MacGregor (BRITAIN - Tags: BUSINESS POLITICS HEALTH EMPLOYMENT)
Sort by
Display
Items per page
Page
of 3